---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-22-000122"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:54:03.242750+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Denali reports Q2 net loss $58.8M; collaboration revenue $52.5M on $40M Sanofi milestone

## Summary
- Net loss $58.8M vs $60.7M year ago; cash and securities $1.16B as of June 30, 2022.
- Collaboration revenue $52.5M, up from $22.9M, driven by $40M milestone from Sanofi (RIPK1) and $12M from Takeda (TREM2 CTA).
- R&D expenses $92.7M (+41% YoY) due to clinical progress in ETV:IDS, LRRK2, and TV platform programs.
- Phase 1 dosing started for DNL919 (ATV:TREM2) in Alzheimer’s; Phase 2b LUMA study for BIIB122 in Parkinson’s underway.
- Initiated Phase 2/3 COMPASS study for DNL310 in Hunter syndrome; data presentations planned for H2 2022.

## SEC filing metadata
- accession: 0001714899-22-000122
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000122/0001714899-22-000122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000122/dnli-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-22-000122
- JSON: https://secwatch.observer/filing/0001714899-22-000122.json
- Plain text: https://secwatch.observer/filing/0001714899-22-000122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.